Clinical Trial Update: Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing brentuximab vedotin for CD30-positive malignant mesothelioma that cannot be removed by surgery; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma | Phase 2 | Status: RECRUITING